Tachyon Receives Funding from CIRM for a Ph 1 Study of TACH101 in Patients with Advanced Solid Tumors
“Therapy resistance and metastatic dissemination are the main challenges in developing effective cancer treatments. Cancer stem cells and tumor-initiating cells play a significant role in this, and until now, have only been poorly characterized. We have completed extensive preclinical studies to support the clinical advancement of TACH101, and we have shown its ability to reduce the population of tumorigenic cells and potently shrink tumors in cancer models,” said Frank Perabo, M.D., Ph.D., CEO of Tachyon Therapeutics. “We are pleased to receive the support of CIRM to advance the first KDM4 inhibitor to enter clinical development.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000